The top affected cancer signaling pathways in PR-low cancers included combined diseases of signal transduction by growth factor receptors and second messengers, peptidyl-tyrosine kinase phosphorylation and modification, transcriptional dysregulation of Hippo–Merlin signaling, PI3K signaling and MAPK signaling. Here, NF2 is linked to cancer.